one8zero8 LLC Purchases Shares of 2,260 Zoetis Inc. (NYSE:ZTS)

one8zero8 LLC acquired a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, HoldingsChannel.com reports. The firm acquired 2,260 shares of the company’s stock, valued at approximately $368,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in Zoetis during the 4th quarter worth approximately $196,651,000. Amundi raised its holdings in shares of Zoetis by 46.2% during the fourth quarter. Amundi now owns 2,748,719 shares of the company’s stock worth $453,355,000 after purchasing an additional 867,993 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Zoetis by 296.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after purchasing an additional 665,331 shares during the period. Nordea Investment Management AB boosted its holdings in Zoetis by 38.3% in the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after purchasing an additional 572,511 shares during the last quarter. Finally, Holocene Advisors LP acquired a new stake in Zoetis during the 3rd quarter worth about $110,809,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock valued at $312,254 in the last 90 days. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent research reports. Stifel Nicolaus lowered their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Barclays increased their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Morgan Stanley cut their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average target price of $215.90.

Zoetis Stock Up 0.8 %

ZTS stock opened at $161.33 on Monday. The stock has a market capitalization of $72.24 billion, a P/E ratio of 29.49, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The firm has a 50-day simple moving average of $166.82 and a 200-day simple moving average of $176.10. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.24%. Zoetis’s payout ratio is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.